Sanofi

Stock Exchange: XPAR • Ticker: SAN • HQ: Paris, France • Employees: 115,631

Ranking by technical area
Ranking by strategic pillar

Performance

Sanofi rises two positions, following improvements in several areas. It takes a clear approach to access management, which includes exploring the link between climate change and health. It performs well in compliance, certifying its sales agents and auditing its operations according to risk. It has expanded its relevant pipeline and is comparatively open with regards to its clinical trial data. It improves in equitable pricing, with more products with equitable pricing strategies. It has recently agreed not to file for or enforce patent rights in Least Developed Countries and low-income countries, and is actively working (via donations) toward the elimination of Human African Trypanosomiasis (HAT). In Capacity Building, Sanofi has been outperformed by peers, despite maintaining its performance overall.

Change since 2014

Innovates in the area of health and climate change, investigating and addressing health- and access-related issues linked to climate change.

Has moved a greater proportion of its R&D projects from one stage of development to another than in the previous reporting period.

Is developing more relevant products, including several new fixed-dose combinations for treating TB and a paediatric formulation of primaquine for malaria.

Has expanded equitable pricing to significantly more products.

Has newly committed to not filing for or enforcing patents in Least Developed Countries or low-income countries.

Has launched a programme with the South African National Department of Health to improve the early detection and management of patients with concomitant diabetes and TB.

Has recently revised its donation policy to take account of additional stages of the donation process (last-mile delivery, safety and quality, etc.)

Opportunities

Expand strong capacity building approach. Sanofi can further improve its strong performance in capacity building in low- and middle-income countries: to target local needs more strategically, including in its ongoing programmes. It can also share more information with relevant stakeholders (e.g., regulatory authorities and distributors) to strengthen supply chains further.

Continue to develop work on climate change and health. Sanofi is encouraged to continue investigating the link between climate change and health. It can incorporate health needs linked to climate change in its R&D priorities, and develop an appropriate implementation strategy. It has already identified disease areas targeted by its products likely to be influenced by climate change: malaria, dengue, cholera, leishmaniasis and animal health.

Consider equitable pricing and licensing more broadly. Sanofi can consider using non-exclusive voluntary licensing to improve access to its products, including those still in development. Likewise, it can extend equitable pricing to more disease areas (e.g., diarrhoeal diseases, lower respiratory infections, ischaemic heart disease, stroke and hypertensive heart disease). Sanofi is currently piloting equitable pricing in some of these areas: it can commit to always considering equitable pricing for products in these disease areas.

Continue to target known needs through innovative and adaptive R&D. Sanofi can continue to target defined, high-priority product R&D needs for low- and middle-income countries, including a range of product types and, in particular, leveraging its strengths in product adaptations.

Prioritise access to products on the WHO EML. Sanofi has the most products on the WHO Model Essential Medicines List (EML). It can assess access barriers to these products in all low- and middle-income countries that need them. It can ensure their availability and affordability, aligning with demand and the availability of alternative products in specific countries.

Sales and operations

Sanofi consists of five business units: Vaccines (Sanofi Pasteur); Diabetes and Cardiovascular; General Medicines and Emerging Markets; Specialty Care; and Animal Health. The Specialty Care unit is focused on: rare diseases, multiple sclerosis, oncology and immunology. In June 2016, Sanofi announced an assets swap with Boehringer Ingelheim, concerning Sanofi’s Animal Health division and Boehringer Ingelheim’s consumer healthcare business. Sanofi has sales in 96 countries in scope. Approximately one third of its sales are generated in emerging markets.

Sales in countries in scope
Sales by division
Sales by region

Portfolio and pipeline

Sanofi has the largest portfolio of relevant products in the Index, with 157 products. It has a large pipeline of 28 R&D projects that address the needs of people in countries in scope.

Sanofi’s portfolio includes medicines and preventive vaccines, medical devices for diabetes, and vector control products for communicable and neglected tropical diseases (NTDs). Its portfolio has a strong focus on diabetes and cardiovascular diseases.

Products per disease category

Sanofi has the most medicines in its portfolio in the Index. It is most active in infectious diseases, ischaemic heart disease and diabetes.

Its pipeline focuses mainly on medicines and vaccines for communicable diseases, covering nine diseases. It is developing products for several NTDs and diabetes. Sanofi has a new project with the Bill and Melinda Gates Foundation to explore the use of Micropellet technology to develop thermostable, cost-effective, novel combination vaccines. Over half of Sanofi’s R&D projects target high-priority product gaps with low commercial incentive. Several of its products have been approved since 2014: e.g., Dengvaxia® gained regulatory approval in several countries in scope in 2015 (including in Brazil, Mexico and the Philippines).

Pipeline projects

Over half of Sanofi’s R&D partnerships include provisions to ensure access. Fexinidazole, in phase III trials for HAT, will be part of its donation programme with WHO.

First-line treatments and essential medicines

A comparatively high proportion of Sanofi’s relevant products are listed on the WHO EML and/or as first-line treatments: e.g., Shan5®, Menactra®, meglumine antimoniate (Glucantime®), and melarsoprol (Arsobal®).

Pipeline by stage of development
– Innovative medicines and vaccines

Sanofi has several innovative vaccines in clinical development, including a trivalent pneumococcal protein vaccine, an HIV/AIDS vaccine, an adjuvanted subunit TB vaccine and a Clostridium difficile vaccine.

Pipeline by stage of development
– Adaptive medicines and vaccines

Sanofi’s pipeline focuses on product adaptations, including four projects to develop fixed-dose combinations for TB, and 2nd-generation vaccines for rabies and meningitis (to extend its use in infants up to 6 months old).

Please refer to the pdf of the report card (that can be downloaded here) for information on Sanofi’s  performance per technical area.

Sign up to receive updates about our work.